REGN लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 42 min ago

@ $951.18

जारी किया गया: 3 May 2024 @ 23:31

वापसी: 0.23%

पिछला सिग्नल: May 2 - 23:57

पिछला सिग्नल: खरीदें

वापसी: 1.79 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 00:14):
Our systems believe the stock currently is overvalued by 0.75% compare to its pairs and should correct downwards.

Stats
आज की मात्रा	234 541
औसत मात्रा	472 833
बाजार मूल्य	103.31B
EPS	$0 ( 2024-05-02 )
अगली कमाई की तारीख	( $10.09 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	27.42
ATR14	$22.96 (2.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Yancopoulos George	Buy	18 148	Common Stock
2024-04-29	Yancopoulos George	Sell	36 296	Common Stock
2024-04-01	Ryan Arthur F	Sell	2	Common Stock
2024-04-01	Ryan Arthur F	Sell	2	Common Stock
2024-04-01	Ryan Arthur F	Sell	9	Common Stock

INSIDER POWER
-30.01
Last 100 transactions
Buy: 249 600 \| Sell: 463 125

सहसंबंध (AI algo v.1.1b): Overvalued: -0.75% $946.91 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: 0.89 (strong)

छोटा: 0.80 (strong)

Signal:(66) Same movement expected

Regeneron Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
CFBK	0.904
NNBR	0.894
VTRS	0.875
PBPB	0.874
GANX	0.866
FTXH	0.862
IMTX	0.862
BKCC	0.859
FXCO	0.853
ARDX	0.848

10 सबसे अधिक नकारात्मक सहसंबंध
OSMT	-0.879
SVOK	-0.85
OPK	-0.847
SEV	-0.833
GHVI	-0.83
RAAC	-0.83
BFRI	-0.83
GOODM	-0.828
MLVF	-0.827
AMTI	-0.807

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Regeneron Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

0.24
( neutral )

0.71
( moderate )

-0.11
( neutral )

0.09
( neutral )

0.06
( neutral )

-0.82
( strong negative )

Regeneron Pharmaceuticals वित्तीय

Annual	2023
राजस्व:	$13.12B
सकल लाभ:	$11.30B (86.16 %)
EPS:	$37.05

FY	2023
राजस्व:	$13.12B
सकल लाभ:	$11.30B (86.16 %)
EPS:	$37.05

FY	2022
राजस्व:	$12.17B
सकल लाभ:	$10.61B (87.18 %)
EPS:	$40.51

FY	2021
राजस्व:	$16.07B
सकल लाभ:	$13.63B (84.83 %)
EPS:	$76.40

Financial Reports:

Symbol	Period	Year	Title
REGN	Q4	2023	Financial Report for REGN - Q4 2023

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.